Your browser is no longer supported. Please, upgrade your browser.
Settings
VINC [NASD]
Vincerx Pharma, Inc.
Index- P/E- EPS (ttm)-3.62 Insider Own12.80% Shs Outstand13.73M Perf Week-13.34%
Market Cap230.55M Forward P/E- EPS next Y-1.71 Insider Trans1.06% Shs Float11.92M Perf Month2.00%
Income-22.90M PEG- EPS next Q-0.38 Inst Own56.40% Short Float6.28% Perf Quarter-17.19%
Sales- P/S- EPS this Y22.10% Inst Trans0.26% Short Ratio5.08 Perf Half Y-30.59%
Book/sh1.86 P/B7.12 EPS next Y-6.90% ROA- Target Price- Perf Year32.73%
Cash/sh3.07 P/C4.32 EPS next 5Y- ROE- 52W Range9.95 - 26.75 Perf YTD-36.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-50.47% Beta-
Dividend %- Quick Ratio1.90 Sales past 5Y- Gross Margin- 52W Low33.17% ATR0.99
Employees28 Current Ratio1.90 Sales Q/Q- Oper. Margin- RSI (14)40.70 Volatility7.84% 7.05%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.88 Prev Close13.97
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume147.30K Price13.25
Recom2.00 SMA20-10.42% SMA50-4.14% SMA200-21.77% Volume128,958 Change-5.15%
Jul-30-21 09:55AM  
Jul-01-21 02:42AM  
Jun-28-21 08:00AM  
Jun-04-21 12:40PM  
08:00AM  
Jun-03-21 04:05PM  
May-26-21 08:00AM  
May-17-21 08:00AM  
May-06-21 08:00AM  
Apr-20-21 08:00AM  
Apr-10-21 08:31AM  
Apr-07-21 08:00AM  
Apr-05-21 08:00AM  
Apr-01-21 08:00AM  
Mar-30-21 09:24AM  
Mar-23-21 08:00AM  
Mar-10-21 04:32PM  
Mar-02-21 08:00AM  
Feb-24-21 08:00AM  
Feb-17-21 08:00AM  
Jan-07-21 04:01PM  
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hwang SooinChief Business OfficerJun 30Buy12.665006,330385,575Jun 30 06:56 PM
Lee John H.DirectorJun 29Buy12.7179910,159799Jul 01 06:52 PM
McDonald Andrew IDirectorJun 29Buy12.3820,000247,60020,000Jul 01 06:05 AM
THOMAS TOM CSee RemarksJun 29Buy12.582,00025,1602,000Jun 30 06:57 PM